PACE-LUNG; IIT; intensification with chemo+osi after induction osi in ctDNA+ persistence. #ESMO26

FLAURA2; ctDNA clearance rates do not differ between 2arms of trial and are prognostic not predictive of PFS/OS; regardless of this combo pts do better #ESMO26

Simplified dermatological Amivantamab strategy; lazertinib 1 cycle lead in lazer then fortnightly Amivantamab….. this seems to be they way to go; interestingly UK cancer drugs fund allows starting 1cycle of lazer first. #ESMO26

DESTINY-Lung 04; #ESMO26 update; PRO’s> some signals favouring the investigational agent. Supports front line delivery of her2 directed therapy. Wouldn’t over interpret this

CROWN trial ctDNA presentations(Guardant infinity). No ALK kinase domain mutations caused acquired resistance. #ESMO26

TROP2 ADC + antiPD1 BAT8008 + BAT1308 first line nonAGA; n104(China only); ORR 61% (83% in PDL1 high); looks better in non squamous. Interesting non chemo front line options? #ESMO26

DeLLphi-305; ES-SCLC; nearly 2y mOS; Strong PFS signal; this is about the strongest data I’ve seen in this space. @BTOGORG #ESMO26

Great DeLLphi-305 discussion by @StephenVLiu ; let’s not forget the drop off post induction; seems to trump lurbi; ICANS and CRS noted but manageable. #ESMO26

Tri-specific anti- PD1-VEGF-CTLA4; activity in multiple cohorts of NSCLC as monotherapy and combination with chemo in different lines; 100% ORR in high PDL1 1st line monotherapy; CS2009 #ESMO26

OSE2101; TEDOPI; in relapsed setting; HLA-A2+ve; signal of benefit in OS endpoints. #ESMO26

IFCT 2103 DIAL; lovely and provocative ; after 6/12 chemo io….no difference between continuation and de-escalation arms….. #ESMO26

SARON; 1-5 mets; 6-8w induction SACT; P2 study:n140; 10y recruitment; SACT used evolved to include IO but valences in arms; no difference in OS; PFS 0.64HR but no difference new sites of disease #ESMO26 @BTOGORG #LCSM Great presentation @fifimcdrmh

PERSÉE; massive benefit for chemoIO over IO in all PDL1 strata in PFS; OS highly suggestive of benefit but NS; I think this is globally practice influencing #ESMO26 @BTOGORG

OptiTROP-Lung06; sacTMT v chemoIO(KN189); n455; open label; PFS HR 0.49; nearly 10m longer mPFS; females magnitude of benefit less; same ORR but double mDOR; tox profile looks interest in stomatitis + ocular. #ESMO26

OptiTROP-Lung04; sacTMT v chemoIO in mEGFR post 3rd gen TKI; OS HR 0.69- 9m longer mOS; they say the stomatitis is manageable #ESMO26 @BTOGORG

Sigvotatug vedotin SV; SigVie-002; n703; in relapsed nonSq NSCLC; 1/3 were AGA post targeted Tx; #ESMO26